SCHEMBL5686

SCHEMBL5686

O=C(O)Cc1ccc(Br)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 1/20 0.52
TSHR P16473 1/20 0.47
GLS O94925 1/20 0.43
ADRA2A P08913 2/20 0.40
ADRA2B P18089 2/20 0.40
ADRA2C P18825 2/20 0.40
PLAU P00749 1/20 0.40
GBA1 P04062 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3759897 0.98 ALDH1A1 (0.50) ALDH1A1KDM4ETSHRGLSADRA2A
Acetamide SCHEMBL1257246 0.91 KDM4E (0.44) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL28126589 0.86 ALDH1A1 (0.48) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL29474748 0.85 ALDH1A1 (0.48) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL27184068 0.85 ALDH1A1 (0.48) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL13754672 0.82 KDM4E (0.46) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL514259 0.82 ADRA2A (0.47) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL3515895 0.81 FFAR1 (0.55) ALDH1A1KDM4ETSHRGLSP4HTM
SCHEMBL19150888 0.79 GBA1 (0.44) ALDH1A1KDM4ETSHRGLSADRA2A
SCHEMBL4178273 0.79 CA2 (0.50) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4302831-B1 PROCESS FOR SYNTHESIS OF TIRBANIBULIN TRIFARMA S P A (IT) 2025-08-27 EP claimed
EP-4302831-A1 PROCESS FOR SYNTHESIS OF TIRBANIBULIN Trifarma S.p.A. (IT) 2024-01-10 EP claimed
EP-4186890-A1 PREPARATION OF N-BENZYL-2-(5-BROMO-PYRIDIN-2-YL)-ACETAMIDE FOR THE SYNTHESIS OF TIRBANIBULIN Moehs Ibérica, S.L. (ES) 2023-05-31 EP claimed
CN-114014850-A Prudelamine intermediate, synthesis method thereof and method for synthesizing prasulamine from intermediate 山东汇海医药化工有限公司 2022-02-08 CN claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
EP-4302831-B1 PROCESS FOR SYNTHESIS OF TIRBANIBULIN TRIFARMA S P A (IT) 2025-08-27 EP disclosed
WO-2025054339-A1 TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT ARCUS BIOSCIENCES, INC. (US) 2025-03-13 WO disclosed
EP-4519259-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. (US) 2025-03-12 EP disclosed
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 CN disclosed
CN-119161306-A Bicycloacetamide structural compound, preparation method and pharmaceutical application thereof 河南大学 2024-12-20 CN disclosed
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
US-20100069328-A1 NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-03-18 US disclosed
US-20100069328-A1 NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-03-18 US disclosed
CN-101501005-A Arylaminoaryl-alkyl-substituted imidazolidine-2, 4-diones, processes for their preparation, medicaments comprising these compounds and their use SANOFI AVENTIS (FR) 2009-08-05 CN disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed
US-20080280910-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2008-11-13 US disclosed
WO-2008114023-A2 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2008-09-25 WO disclosed
CN-101001842-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-07-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069328-A1 NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER IL4I1, MKI67, ABL1 ALDH1A1 657/4885KDM4E 846/4885TSHR 3771/4885
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 ALDH1A1 2836/4885KDM4E 406/4885TSHR 729/4885
US-20080280910-A1 PHTHALAZINONE DERIVATIVES H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, NCOA4 ALDH1A1 2515/4885KDM4E 1441/4885TSHR 3275/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 ALDH1A1 3556/4885KDM4E 2322/4885TSHR 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.